Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02257216 · ClinicalTrials.gov registry record · NA
Vayarin® Medical Food Study for Adults With Attention Deficit Hyperactivity Disorder (ADHD)
A NA study, sponsored by Enzymotec.
- Completed
- Registry status
- NA
- Development phase
- 171
- Enrollment target
NCT02257216: Completed NA study, sponsored by Enzymotec.
NCT02257216 is a NA study that has completed, run by Enzymotec. The registered enrollment target is 171 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02257216, a NA study, has completed, sponsored by Enzymotec.
- COMPLETED
- Registry status
- NA
- Development phase
- 171 participants
- Enrollment target
Study Summary
The primary study objective is to evaluate the efficacy of Vayarin in ADHD adults.
Interventions
- OTHER Placebo
- OTHER Vayarin®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2014-10 |
| Est. Completion | 2017-06 |
| Phase | NA |
What the finished NCT02257216 record still lists
NCT02257216 is an interventional study that assigns participants to a tested intervention. The registered 171 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02257216 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02257216 about?
NCT02257216 is a clinical study titled "Vayarin® Medical Food Study for Adults With Attention Deficit Hyperactivity Disorder (ADHD)". The primary study objective is to evaluate the efficacy of Vayarin in ADHD adults.
What is the current status of trial NCT02257216?
This trial is currently completed. It is a NA study. The enrollment target is 171 participants. The study started on 2014-10. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02257216?
The interventions under investigation include: Placebo (OTHER), Vayarin® (OTHER).
Who is sponsoring clinical trial NCT02257216?
This trial is sponsored by Enzymotec, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02257216's enrollment target sits among peer trials
171 612th of 2000 higher than 1,387 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02641145 · 171 participants · NA
Molecular Imaging of Primary Amyloid Cardiomyopathy
- NCT05541029 · 171 participants · NA
Music Listening: A Mechanistic Trial
- NCT05561127 · 171 participants · Phase 3
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel
- NCT05592938 · 171 participants · NA
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia